Handok, which had previously stopped selling the insulin biosimilar ‘Glarzia (insulin glargine)', will be marketing and distributing the original insulin 'Lantus' from the 1st of next month.

Whether the company will be able to expand its presence in the diabetes treatment market with the original product based on the know-how in insulin sales it had accumulated selling Glarzia is gaining attention.

According to industry sources on the 28th, Handok will be in charge of the marketing and sales of Lantus Injection Solostar and Lantus Injection Vial that is being imported and marketed by Sanofi-Aventis Korea from August 1st.

Lantus is a long-acting insulin injected once a da